Article

Olive Oil May Stop Brain Cancer from Forming

Compound in olive oil inhibits disease activity of certain proteins.

A compound in olive oil may help prevent the development of brain cancer, a new study published in the Journal of Molecular Biology suggests.

Oleic acid is a monounsaturated fatty acid present in olive oil. Prior studies have shown it can inhibit the disease-causing activity of specific proteins.

Based on this information, the authors of the current study sought to examine how oleic acid affects miR-7 activity. MiR-7 is a microRNA that is active in the brain and known to suppress tumor formation.

The investigators tested the effects of oleic acid on both human cell extracts and in living cells in the lab.

The results of the study showed that the compound inhibited the activity of the protein Musashi homolog2, preventing the protein from halting miR-7 production and ultimately preventing brain tumors from forming.

Although the investigators were unable to conclude whether dietary intake of olive oil protects against brain cancer, they believe their findings could pave the way for new strategies to prevent the disease.

“While we cannot yet say that olive oil in the diet helps prevent brain cancer, our findings do suggest that oleic acid can support the production of tumor-suppressing molecules in cells grown in the lab,” said lead investigator Dr Gracjan Michlewski. “Further studies could help determine the role that olive oil might have in brain health.”

The authors noted that more research needs to be done to determine whether olive oil consumption can help prevent brain cancer, but “these results suggest that [oleic acid] can be important and a specific regulator of RNA processing events,” the authors concluded.

The American Brain Tumor Associated estimates that 80,000 new cases of primary brain tumors will be diagnosed this year in the United States. Of these, approximately 26,000 will be malignant.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards